Essential Medicines Are More Available than Other Medicines around the Globe
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an inconsistent pattern in the availability of essential medicines. We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels. METHODS: Medicine availability in the public and private sector were calculated based on data obtained from national and provincial facility-based surveys undertaken in 23 countries using the WHO/HAI methodology. The medicines were grouped according to their inclusion ('essential') or exclusion (termed 'non-essential') in each country's EML current at the time of the survey. Availability was calculated for originator brands, generics and any product type (originator brands or generics) and compared between the two groups. Results were aggregated by WHO regions, World Bank country income groups, a wealth inequality measure, and therapeutic groups. FINDINGS: Across all sectors and any product type, the median availability of essential medicines was suboptimal at 61·5% (IQR 20·6%-86·7%) but significantly higher than non-essential medicines at 27·3% (IQR 3·6%-70·0%). The median availability of essential medicines was 40·0% in the public sector and 78·1% in the private sector; compared to 6·6% and 57·1% for non-essential medicines respectively. A reverse trend between national income level categories and the availability of essential medicines was identified in the public sector. INTERPRETATION: EMLs have influenced the provision of medicines and have resulted in higher availability of essential medicines compared to non-essential medicines particularly in the public sector and in low and lower middle income countries. However, the availability of essential medicines, especially in the public sector does not ensure equitable access.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calamita, E., Schmid, M., Kunz, M., Ndebele-Murisa, M. R., Magadza, C. H. D., Nyambe, I., & Wehrli, B. (2019) · Figshare · doi:10.26181/6153922fe919c · Cited by 4,222
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928 · cited 3×
“The noticeable contribution of originator brand products to overall availability and extremely high prices of medicines compared to international reference prices [7] indicates the value of moving towards implementation of universal reimbursement systems that ensure equitable access to medicines for the entire society…”
Self-citationSodergren, E. H. (2007) · Cited by 257
Cameron, A., Roubos, I., Ewen, M., Mantel-Teeuwisse, A. K., Leufkens, H. G., & Laing, R. O. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.10.084327 · Cited by 187 · cited 3×
“[8] In our study, cardiovascular (antihypertensive and lipid modifying agents) and psychoanaleptic medicines were among the therapeutic groups for which the availability of essential medicines was far greater than non-essential medicines.”
Self-citationvan Mourik, M. S., Cameron, A., Ewen, M., & Laing, R. O. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-25 · Cited by 180 · cited 1×
“Several studies included assessments of the availability of medicines for acute versus chronic conditions [8], cardiovascular medicines in developing countries [9], anti-”
BackgroundSelf-citationCameron, A., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Laing, R. O. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.004 · Cited by 177 · cited 1×
“[33,34] The suboptimal availability of essential medicines in the public sector was observed in all WHO regions.”
Self-citationYang, H., Dib, H. H., Zhu, M., Qi, G., & Zhang, X. (2009) · Health Policy and Planning · doi:10.1093/heapol/czp056 · Cited by 87 · cited 1×
“[19] Conversely, a national study on the availability of pediatric essential medicines in Sri Lanka’s public sector [20] as well as provincial surveys on national essential medicines in China [21,22] all pointed to inadequate availability of the essential medicines studied.”
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
Bertoldi, A. D., Helfer, A. P., Camargo, A. L., Tavares, N. U. L., & Kanavos, P. G. (2012) · Globalization and Health · doi:10.1186/1744-8603-8-6 · Cited by 80 · cited 1×
“Above 75% average availability of generic medicines was reported in a national survey of essential medicines in the private sector in Sri Lanka [15] and in the public sector and popular pharmacies in Brazil [16], as well as in provincial surveys on essential medicines in Ethiopia [17], primary health care centers’ ess…”
Chen, W., Tang, S., Sun, J., Ross-Degnan, D., & Wagner, A. K. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-211 · Cited by 79
Availability of essential medicines in Ethiopia: an efficiency‐equity trade‐off?
Carasso, B. S., Lagarde, M., Tesfaye, A., & Palmer, N. (2009) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2009.02383.x · Cited by 67 · cited 1×
“Above 75% average availability of generic medicines was reported in a national survey of essential medicines in the private sector in Sri Lanka [15] and in the public sector and popular pharmacies in Brazil [16], as well as in provincial surveys on essential medicines in Ethiopia [17], primary health care centers’ ess…”
Cited by
Drug Shortage: Causes, Impact, and Mitigation Strategies
Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A. H., Omer, S., Hu, S., Babar, Z.-U.-D., Fang, Y., & Yang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693426 · Cited by 322
Agyepong, I. A., Sewankambo, N., Binagwaho, A., Coll-Seck, A. M., Corrah, T., Ezeh, A., Fekadu, A., Kilonzo, N., Lamptey, P., Masiye, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31509-x · Cited by 245
Seidman, G., & Atun, R. (2017) · BMJ Global Health · doi:10.1136/bmjgh-2016-000243 · Cited by 133
Husain, M. J., Datta, B. K., Kostova, D., Joseph, K. T., Asma, S., Richter, P., Jaffe, M. G., & Kishore, S. P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015302 · Cited by 120
Selection and Use of Essential Medicines
Moja, L., & Huttner, B. D. (2023) · Sustainable development goals series · doi:10.1007/978-3-031-33851-9_49 · Cited by 107
Kasonde, L., Tordrup, D., Naheed, A., Zeng, W., Ahmed, S., & Babar, Z. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4221-z · Cited by 101
The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study
Khuluza, F., & Häfele-Abah, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212125 · Cited by 79
“Malawi as a country is doing well in the availability of adult antibiotics, especially amoxicillin, ciprofloxacin, cotrimoxazole tablets, gentamicin injections and metronidazole tablets which showed an availability of more than 80% in all sectors as recommended by the WHO [15, 16].”
BackgroundInfluentialKishore, S. P., Blank, E., Heller, D. J., Patel, A. J., Peters, A., Price, M. J., Vidula, M. K., Fuster, V., Onuma, O. K., Huffman, M. D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.056 · Cited by 65
“Today, at least 34 countries have national EMLs, and 94% of those countries report using the WHO EML as their basis for public procurement (6).”
BackgroundInfluentialSado, E., & Sufa, A. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0572-3 · Cited by 57
“These findings are inconsistent with other studies of affordability of adult medicines which showed unaffordability of chronic medicines rather than drugs for infectious treatment for low income populations [10, 29] and consistent with study of affordability in the Haiti [26].”
ResultMedicine shortages in Fiji: A qualitative exploration of stakeholders’ views
Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., & Moles, R. J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178429 · Cited by 57
Guadamuz, J. S., Shooshtari, A., & Qato, D. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061350 · Cited by 56
Masters, S. H., Burstein, R., DeCenso, B., Moore, K., Haakenstad, A., Ikilezi, G., Achan, J., Osei, I., Garshong, B., Kisia, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114762 · Cited by 55
“Multiple studies have synthesized relevant data from numerous WHO/HAI surveys to generate medicine availability estimates [13, 14].”
BackgroundAdekoya, I., Maraj, D., Steiner, L., Yaphe, H. M., Moja, L., Magrini, N., Cooke, G., Loeb, M. B., & Persaud, N. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30854-9 · Cited by 61
Salam, A., Huffman, M. D., Kanukula, R., Prasad, E. H., Sharma, A., Heller, D. J., Vedanthan, R., Agarwal, A., Rodgers, A., Jaffe, M. G., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14009 · Cited by 50
Affordability of medicines in the European Union
Zaprutko, T., Kopciuch, D., Kus, K., Merks, P., Nowicka, M., Augustyniak, I., & Nowakowska, E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172753 · Cited by 45
Muluye, A. B., Desta, A. G., Abate, S. K., & Tiruneh, G. (2019) · Malaria Journal · doi:10.1186/s12936-019-2887-7 · Cited by 43
Availability and affordability of antimalarial and antibiotic medicines in Malawi
Khuluza, F., & Heide, L. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175399 · Cited by 41
Essential medicines for breast cancer in low and middle income countries
Bazargani, Y. T., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2015) · BMC Cancer · doi:10.1186/s12885-015-1583-4 · Cited by 40
“Previous research showed that in general essential medicines selected on NEMLs were more available than those not selected as essential medicines, highlighting the importance of adequate selection to ensure optimal access [44].”
Self-citationSchäfermann, S., Neci, R., Ndze, E. N., Nyaah, F., Pondo, V. B., & Heide, L. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227515 · Cited by 44
Lavtepatil, S., & Ghosh, S. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08022-1 · Cited by 45
Essential medicines availability is still suboptimal in many countries: a scoping review
Mahmić-Kaknjo, M., Kadić, A. J., Utrobičić, A., Chan, K. Y., Bero, L. A., & Marušić, A. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.02.006 · Cited by 38
“Provision and availability of EMs (measured using WHO/Health Action International (HAI) methodology and WHO operational package for monitoring and assessing country pharmaceutical situations) [30,31] has improved (over 2003-2011 time period) compared to non-EMs in low- and lower middle-income countries, especially in…”
BackgroundMethodGovender, T., Suleman, F., & Perumal-Pillay, V. A. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00390-z · Cited by 31
“A global study that analysed the data of 23 countries from the World Health Organization (WHO)/Health Action International database in 2014 looked at the implementation of STGs/EML and found that essential medicines were more available than non-essential medicines in all health care institutions (both public and priva…”
BackgroundBazargani, Y. T., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106072 · Cited by 34
“Essential medicines are medicines which satisfy the priority health care needs of societies and are considered as a basis for public procurement or reimbursement decisions [9,10].”
Self-citationGlobal sales of oral antibiotics formulated for children
Li, G., Jackson, C., Bielicki, J. A., Ellis, S., Hsia, Y., & Sharland, M. (2020) · Bulletin of the World Health Organization · doi:10.2471/blt.19.235309 · Cited by 29
Access to cardiovascular medicines in low- and middle-income countries: a mini review
Harrison, M. A., Marfo, A. F. A., Annan, A., & Ankrah, D. (2023) · Global Health Research and Policy · doi:10.1186/s41256-023-00301-6 · Cited by 37
“3% availability for non EML medicines [49].”
BackgroundAgarwal, A., Husain, M. J., Datta, B. K., Kishore, S. P., & Huffman, M. D. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008971 · Cited by 28
Essential Diagnostics for the Use of World Health Organization Essential Medicines
Schroeder, L. F., Guarner, J., & Amukele, T. K. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.275339 · Cited by 30
“A recent study found that in World Bank lowincome economies, medicines from national EMLs had nearly 50% availability, whereas medicines not on national EMLs had 10% availability (25).”
BackgroundSharma, A., Rorden, L., Ewen, M. A., & Laing, R. O. (2016) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-016-0059-5 · Cited by 26
“While access has improved considerably since the introduction of the essential medicines concept in 1977, one-third of the world’s population is still not treated with the needed medicines [2–5].”
BackgroundSelf-citationHaque, M. (2017) · Journal of International Society of Preventive and Community Dentistry · doi:10.4103/jispcd.jispcd_224_17 · Cited by 31
“[54] Although the Indian scenario regarding utilization of EM has improved, nonetheless, lot more to go to ensure health care for all.[32,55]”
BackgroundRegistration and local production of essential medicines in Uganda
Brhlíková, P., Maigetter, K., Murison, J., Agaba, A. G., Tusiimire, J., & Pollock, A. M. (2020) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00234-2 · Cited by 28
“essential medicines are more available than nonessential medicines in both public and private sectors [3].”
BackgroundSaeed, A., Saeed, F., Saeed, H., Saleem, Z., Yang, C., Chang, J., Jiang, M., Zhao, M., Saqlain, M., Ji, W., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595008 · Cited by 25
“While doing this analysis, they categorized the medicines into essential and non-essential (not included into the NEML) and found that the availability of both types of medicines was suboptimal but the essential medicines had better availability than the non-essential medicines, corroborating our findings (Bazargani e…”
ResultSocietal value of generic medicines beyond cost-saving through reduced prices
Dylst, P., Vulto, A. G., & Simoens, S. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1017565 · Cited by 30
Bagonza, J., Rutebemberwa, E., Eckmanns, T., & Kiracho, E. E. (2015) · BMC Public Health · doi:10.1186/s12889-015-2525-4 · Cited by 28
“Although literature on the assessment of drug availability in the formal health sector is widely available [24–26], medicine availability for community case management programmes for childhood malaria, pneumonia and diarrhea has not been fully documented in Uganda.”
BackgroundJarvis, J. D., Woods, H., Bali, A., Oronsaye, E., & Persaud, N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220781 · Cited by 22
Ward, C. L., Guo, M. Z., Amukele, T. K., Abdul-Karim, A., & Schroeder, L. F. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa190 · Cited by 24
Todesco, B., Ostuzzi, G., & Barbui, C. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000087 · Cited by 22
Guo, Z., Guan, X., & Shi, L. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2698-x · Cited by 26
Guan, X., Tian, Y., Ross‐Degnan, D., Man, C., & Shi, L. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022328 · Cited by 20
Availability, Sales, and Affordability of Tobacco Cessation Medicines in Kerala, India
Bhaumik, S. S., Harikrishnan, S., Baldridge, A. S., Devarajan, R., Mehta, A., Selvaraj, S., Ali, M. K., Mohanan, P. P., Prabhakaran, D., & Huffman, M. D. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.004108 · Cited by 21
Yang, L., Huang, C., & Liu, C. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2720-3 · Cited by 19
“The NEMP aims to improve availability, affordability, and quality use of medicines in primary care facilities [16, 17].”
BackgroundThe case for an essential medicines list for Canada
Eom, G. D., Grootendorst, P. V., & Duffin, J. M. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.160134 · Cited by 18
Piggott, T., Moja, L., Akl, E. A., Lavis, J. N., Cooke, G., Kredo, T., Hogerzeil, H. V., Huttner, B. D., Alonso‐Coello, P., & Schünemann, H. J. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.12.007 · Cited by 18
Brhlíková, P., Deivanayagam, T. A., Babar, Z., Osorio-de-Castro, C. G. S., Caetano, R., & Pollock, A. M. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00595-4 · Cited by 19
“However the availability of EMs remains suboptimal globally [7, 45, 46].”
BackgroundHailu, A. D., & Mohammed, S. A. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01247-2 · Cited by 17
Essential Medicine List, Policies, and the World Health Organization
Atif, M., Malik, I., Dawoud, D., Gilani, A. H., Ahmed, N., & Babar, Z. (2019) · Huddersfield Research Portal (University of Huddersfield) · Cited by 17
Global disparities in arrhythmia care: Mind the gap
Sharif, Z. I., & Ptaszek, L. M. (2022) · Heart Rhythm O2 · doi:10.1016/j.hroo.2022.09.007 · Cited by 18
“Placing a limited number of carefully selected medications on an essential medical list is one way for LMICs to prioritize the purchase of specific medications.(55) Underutilization of OACs is due to several factors that disproportionately impact resource-constrained environments.”
BackgroundRegistration of essential medicines in Kenya, Tanzania and Uganda: a retrospective analysis
Green, A., Lyus, R., Ocan, M., Pollock, A. M., & Brhlíková, P. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231181263 · Cited by 20
Nsabagasani, X., Ogwal-Okeng, J. W., Mbonye, A. K., Ssengooba, F., Muhumuza, S., & Hansen, E. H. (2015) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-015-0038-2 · Cited by 16
“Funding for essential medicines is essential to ensure access to the medicines for the patients who need the medicines [13].”
BackgroundSieleunou, I., Turcotte‐Tremblay, A., Allegri, M. D., Fotso, J.-C. T., Yumo, H. A., Tamga, D. M., & Ridde, V. (2019) · Health Policy and Planning · doi:10.1093/heapol/czz084 · Cited by 22
“More recent research in 23 low- and middle-income countries did not find considerable progress, indicating the median availability of EMs at only 40% (Bazargani et al., 2014).”
BackgroundWang, X., He, X., Ren, Y., Zhang, Z., Cai, L., Cao, Z., & Li, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.860471 · Cited by 13
“Similar conclusions were drawn in other studies, namely that there is a shortage of EMs, particularly in the public sector (6).”
ResultNOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
Cesare, M. D., Jarvis, J. D., Scarlatescu, O., Leng, X., Zaidel, E. J., Burrone, E., Eiselé, J.-L., Prabhakaran, D., & Sliwa, K. S. (2020) · Global Heart · doi:10.5334/gh.774 · Cited by 13
“be overcome to ensure equitable access to essential medicines [29, 30].”
BackgroundAvailability, pricing, and affordability of essential medicines for pediatric population in Malawi
Chiumia, F. K., Chithope-Mwale, C., Abikoloni, F., Matchaya, V., Gaviyawo, T., & Khuluza, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379250 · Cited by 14
Diagnostic and Therapeutic Practice for HFpEF Across Continents and Regions: An International Survey
Ingimarsdóttir, I. J., Vishram‐Nielsen, J. K. K., Einarsson, H., Goldfeder, S., Mewton, N., Barasa, A. L., Basic, C., Oerlemans, M. I. F. J., Niederseer, D., Shchendrygina, A., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15084 · Cited by 12
“24 A cross-sectional analysis on national EMLs in 53 countries in the Americas, Africa, Eastern-Mediterranean, South-Eastern Asia, and Western Paci fi c, showed that 47% of the countries included all four pillars of GDMT. 25 Interestingly beta-blockers were on the fewest number of national EMLs (32%…”
Magarinos‐Torres, R., Lynd, L. D., Luz, T. C. B., Marques, P. E. P. C., & Osorio-de-Castro, C. G. S. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12783 · Cited by 15
Li, D. G., Najafzadeh, M., Kesselheim, A. S., & Mostaghimi, A. (2019) · BMJ · doi:10.1136/bmj.l4257 · Cited by 12
The interpretation of China national essential medicines list 2018
Zuo, W., Mei, D., Sun, W., Tang, X., Niu, Z., Gao, D., & Zhang, B. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1713749 · Cited by 11
“Since the first edition of WHO-EML was issued in 1977, more than 156 countries have established their own EML using the WHO-EML as their basis for public procurement [2].”
MethodExpanding medicines for neurologic disorders on the WHO Model List
Rimmer, K., Shah, H., & Thakur, K. (2017) · Neurology · doi:10.1212/wnl.0000000000003691 · Cited by 11
A comparison of national essential medicines lists in the Americas
Steiner, L., Maraj, D., Woods, H., Jarvis, J. D., Yaphe, H. M., Adekoya, I., Bali, A., & Persaud, N. (2020) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2020.5 · Cited by 11
Pediatric Rheumatic Disease in Lower to Middle-Income Countries
Scott, C., Sawhney, S., & Lewandowski, L. B. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.09.001 · Cited by 10
Hassan, A. N., Gobir, A. A., Ahmed, A. A., Sabiu, A., John, U., Ezekeil, G., & Ibrahim, Y. A. (2017) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2017.03.006 · Cited by 10
“A study by Bazargani et al revealed that EMLs have influenced the provision of medicines and have resulted in a higher availability of essential medicines compared to nonessential medicines particularly in the public sector and in low and lower middle income countries.(13) The findings revealed that the overall median…”
BackgroundLotfizadeh, A., Palafox, B., Takallou, A., Balabanova, D., McKee, M., & Murphy, A. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000072 · Cited by 11
“Bazargani 2014 [20] Physical presence of drug Proportion of facilities where medicine was available Not stated Not stated”
InfluentialBruno, O. (2015) · Journal of Pharmaceutical Care & Health Systems · doi:10.4172/2376-0419.s2-006 · Cited by 10
“Other authors have pointed out that sustainable adequate funding and use of supply chain management techniques are equally important considerations that can ensure that patients have access to essential medicines [25].”
BackgroundMohan, S., Mangal, T. D., Colbourn, T., Chalkley, M., Chimwaza, C., Collins, J. H., Graham, M. M., Janoušková, E., Jewell, B. L., Kadewere, G., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00095-0 · Cited by 9
Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations
Todesco, B., Ostuzzi, G., Gastaldon, C., Papola, D., & Barbui, C. (2023) · Archives of Public Health · doi:10.1186/s13690-022-01014-x · Cited by 9
“Alignment of national EMLs to the WHO Model List can facilitate access to essential medicines, particularly in the public sector and in low resource settings [5].”
MethodAvailability of Access, Watch, and Reserve groups of essential antibiotics: a cross-sectional survey
Rafi, S., Anjum, S. M., Usman, M. A., Nawaz, H. A., Chaudhry, M., Babar, Z., & Rasheed, H. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1251434 · Cited by 8
Kirby, J., Ojha, R. P., Johnson, K. M., Bittner, E. C., & Caniza, M. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25273 · Cited by 8
Ostuzzi, G., Gastaldon, C., Papola, D., & Barbui, C. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000166 · Cited by 12
“These figures are worrisome, as inclusion of a particular medicine in national EMLs has been shown to result in higher availability, particularly in the public sector and in LMICs (Bazargani et al., 2014).”
BackgroundSelf-reflection promotes learning in citizen science and serves as an effective assessment tool
Golumbic, Y. N., Motion, A., Chau, A., Choi, L., D'Silva, D., Ho, J., Nielsen, M., Shi, K. Y., Son, C. D., Wu, O., et al. (2022) · Computers and Education Open · doi:10.1016/j.caeo.2022.100104 · Cited by 19
Babigumira, J. B., Lubinga, S. J., Jenny, A. M., Larsen-Cooper, E., Crawford, J., Matemba, C., & Stergachis, A. S. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2530-7 · Cited by 10
“The public sector availability of essential medicines in 23 LMICs in 2012 was estimated at only a mean value of 40% [3].”
BackgroundThe Political Economy of the World Health Organization Model Lists of Essential Medicines
Jenei, K. (2025) · Milbank Quarterly · doi:10.1111/1468-0009.70001 · Cited by 7
Bibi, M., Haq, N. U., Kareem, A., Ullah, H., Baloch, N., Rehman, G., & Nasim, A. (2022) · International Journal of Public Health · doi:10.3389/ijph.2022.1604375 · Cited by 7
“It was estimated that almost half of the world’s population still lacks access to lifesaving medicines [9].”
BackgroundAntibiotic use in public hospitals in Vietnam between 2018 and 2022: a retrospective study
Dat, V. Q. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-087322 · Cited by 13
“Further works need to be done to investigate the feasibility, effectiveness and acceptability of using The WHO AWaRe antibiotic book 31 as a guidefor clinical management of common infections in children and adults in the setting of high prevalence of antibiotic resistance.”
BackgroundAn analysis of the essential medicines policy in primary care: Findings from MedMinas project
Luz, T. C. B., Tavares, N. U. L., Marques, I. C., de Castro, A. K. S., & Cota, B. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.953329 · Cited by 7
“Theoretically, one of the major benefits of implementing an EMP is achieving more regular and efficient medicines supply processes (Bazargani et al., 2014); however, our evidence does not support this assumption.”
BackgroundMuiruri, C. (2017) · University of Nairobi Research Archive (University of Nairobi) · Cited by 6
Yang, R., Li, Q., Hayat, K., Zhai, P., Liu, W., Chen, C., Saeed, A., Chang, J., Li, P., Du, Q., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.895649 · Cited by 6
Saeed, A., Shukar, S., Yasin, N. A., Yang, C., Jiang, M., Aziz, M. M., Zahoor, H., Sunnan-Ud-Din, M., Fang, Y., & Babar, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1627735 · Cited by 6
“Although the NEML OADs were slightly more available, there was no signi fi cant difference between the availability of NEML and non-NEML medicines, which is contrary to the fi ndings by other researchers (Bazargani et al., 2014).”
Hellamand, M., Moleman, T., Post, A. P., Mantel-Teeuwisse, A. K., Suleman, F., & van den Ham, H. A. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018550 · Cited by 6
Self-citationМаратовна, Р. Ч., & Зиганшина, Л. Е. (2017) · Kazan medical journal · doi:10.17750/kmj2017-822 · Cited by 4
Access to Essential Medicines for Circulatory Diseases: A Call to Action
McKee, M., Scarlatescu, O., Wood, D., Eiselé, J.-L., Perel, P., & Yusuf, S. (2019) · Global Heart · doi:10.1016/j.gheart.2019.07.008 · Cited by 4
“A review of facility surveys in 23 low- and middle-income countries found that the median availability of essential generic medicines was 53% but the interquartile range was from only 15% to 83% [5].”
BackgroundKanamori, S., Egami, Y., Shimizu, E., Miyano, S., Villanueva, A. F. D. R., Hashimoto, N., Kiyohara, H., Norizuki, M., Uechi, M., Koto‐Shimada, K., et al. (2025) · Tropical Medicine and Health · doi:10.1186/s41182-025-00839-w · Cited by 3
“Successful cases have shown that the EML improved access to essential medicines by enhancing procurement and supply chains [25]; lowering prices, thereby reducing out-of-pocket expenditures for patients [26]; and facilitating the registration of WHO-pre-qualified products [27].”
Establishing links between drug registers and essential medicine lists
Brhlíková, P., Babar, Z., & Pollock, A. M. (2025) · Bulletin of the World Health Organization · doi:10.2471/blt.24.291512 · Cited by 5
Maraj, D., Steiner, L., & Persaud, N. (2022) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2022.100305 · Cited by 3
Pastakia, S. D., Njuguna, B., & Tran, D. N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811228-1.00023-6 · Cited by 4
Essential diabetes medicines and health outcomes in 127 countries
BUDHRAM, D. R., Benipal, S., Bilimoria, K., Maraj, D., Wang, R., & Persaud, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14316 · Cited by 3
“Generally, these lists have influenced the provision of medicines and have resulted in higher availability of essential medicines compared with non-essential medicines.(9) These lists contain essential diabetes medicines intended to meet the priority health care needs of a population, but the selection of these medici…”
BackgroundMachado, I. K., Lippert, C. N., & Ostacher, M. J. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152245 · Cited by 1
Biologic medicine inclusion in 138 national essential medicines lists
Kraus, R., Yeung, R. S. M., & Persaud, N. (2021) · Pediatric Rheumatology · doi:10.1186/s12969-021-00608-z · Cited by 4
“The inclusion of medications in EMLs has been shown to decrease their cost, increase availability, and improve patient outcomes over time [23, 24].”
BackgroundBabatunde, D., Pollock, A. M., Ocan, M., & Brhlíková, P. (2024) · JRSM Open · doi:10.1177/20542704241232814 · Cited by 2
“37,38 41 Our fi ndings support previous recommendations that STG-recommended medicines should be aligned with EMLs to reduce and control medicine prices and improve medicine access and availability.”
BackgroundHaq, M. Z. U., Heredia, C., Buadu, A., Rizvi, A., Workentin, A., & Persaud, N. (2024) · BMC Cancer · doi:10.1186/s12885-024-13247-w · Cited by 2
Wireko, F. W., Miller, A., Touray, S., & Sefa, N. (2025) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2025.2587465 · Cited by 2
“The Essential Medicines List (EML) has helped populations in Low-and Middle-Income Countries (LMICs) obtain discounts from pharmaceutical companies on the most important medications required for health delivery in these countries (Bazargani et al., 2014; Kishore et al., 2011).”
Golumbic, Y. N., Scroggie, K. R., Kenneally, C., Lin, J., Blyth, M. T., Firmer, G., Rutledge, P. J., & Motion, A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054242 · Cited by 2
“The list is intended to guide governments in making decisions regarding which medicines should have regulatory approval on a national level (authority to be prescribed and sold), as well as economic support such as government subsidies, and to lead to improved accessibility [5].”
BackgroundSubstantion of social effective directions for improvinq druq prink
Немченко, А. С., & Назаркіна, В. М. (2016) · Social pharmacy in health care · doi:10.24959/sphhcj.16.50 · Cited by 2
“Позитивний вплив на стабілізацію цін справляють переговори між державою, виробниками ліків та страховими фондами щодо оптимізації витрат на охорону здоров’я [12, 13, 15].”
Karwa, R., Tran, D. N., Maina, M., Njuguna, B., Manji, I., Wasike, P., Tonui, E. C., Kigen, G., & Pastakia, S. D. (2017) · ACS symposium series · doi:10.1021/bk-2017-1267.ch009 · Cited by 3
Medicines Pricing Policy and Strategies in Developing Countries
Rida, N. A., & Ibrahim, M. I. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811228-1.00007-8 · Cited by 2
Availability of essential medicines in primary care in Vietnam
Thuy, H. T., Ha, D. T., Tuong, P. V., Thinh, C. Q., & Nga, N. T. T. (2020) · International Journal of Healthcare Management · doi:10.1080/20479700.2020.1756093 · Cited by 2
Essential tobacco dependence medicines in 137 countries
Benipal, S., BUDHRAM, D. R., Bilimoria, K., Woods, H., Wang, R., & Persaud, N. (2020) · Addiction · doi:10.1111/add.15282 · Cited by 2
International practices of pricing-management as the basis of availability of medicines
Назаркіна, В. М., & Немченко, А. С. (2017) · Social pharmacy in health care · doi:10.24959/sphhcj.17.83 · Cited by 2
Ojo, T., Saxena, E., & Persaud, N. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086459 · Cited by 1
Wuresah, I., Brooks, A. D., Kubal, N., Gold, M., Krolewiecki, A. J., & Jacobson, J. (2026) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0014458 · Cited by 1
“They were limited in coverage, such as focusing on a narrow sub-national areas, [54,55], also used the SARA dataset [56] or were not clearly inclusive of STH-related medicines [55,57].”
Acharya, M. (2016) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000156 · Cited by 2
“Essential medicines in general are more available than non-essential ones, reflecting as it does the significance of the concept[30].”
BackgroundIyengar, S., van den Ham, R., & Suleman, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813166-4.00007-3 · Cited by 1
Metadata
- Authors
- Bazargani, Y. T., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K.
- Affiliations
- Utrecht University (NL)
- Health Action International (NL)
- Corresponding author
- Mantel-Teeuwisse, Aukje K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-12
- Volume
- 9
- Issue
- 2
- Pages
- e87576
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3922716
- OpenAlex
- W2149749469
- Cited by
- 126
- References
- 31
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 17 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 7 · 2017: 20 · 2016: 5 · 2015: 6 · 2014: 3
- FWCI
- 28.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines, drug availability, National List of Essential Medicines, World Health Organization, public sector, private sector, generic drugs, health equity, country income level, WHO regions, therapeutic groups, pharmaceutical access
- MeSH terms
- Health Services Accessibility, Health Services Needs and Demand, Humans, Global Health, World Health Organization, Private Sector, Public Sector, Drugs, Essential, Prescription Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.